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sions included no evidence of a diabetes diagnosis prior to study intervals or death 
prior to the end of intervals. Indicated services based on ADA guidelines for lipid (LI) 
, retina examinations (RE), microalbuminuria (MA), serum creatinine (SC), inﬂuenza 
vaccinations (FV), and A1c tests were identiﬁed from CPT codes and HCPCS codes 
(≥ 2 annually for A1c tests and ≥1 annually for other tests). Logistic regression assessed 
associations between subprogram and assessments controlling for age, gender, ethnic-
ity, comorbidity, and state region. RESULTS: A sample of 22,017 persons, with 57% 
FFS, 26% CM and 17% MC was identiﬁed. Overall, proportions (95% C.I.) meeting 
recommendations were 63.5%, (62.9 – 64.1) SC, 37.2% (36.5 – 37.8) LI, 30.5% (29.9 
– 31.1) RE, 23.3% (22.8 – 23.9) MA, 18.2% (17.6 – 18.7) FV, and 15.6% (15.1 – 
16.1) A1c tests. Compared to FFS, odds ratios ranged from 1.38 for RE to 4.74 for 
LI under CM and excluding RE which did not differ, 1.39 for FV to 3.78 for LI under 
MC (P ≤ 0.001 for all). CONCLUSIONS: While A1c rates are likely low due to low 
claims submission for point of service A1c tests, other rates are likely representative. 
Associations between subprograms and assessments may indicate strategies such as 
chronic disease management and primary care coordination may be effective in 
increasing diabetes care assessments.
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OBJECTIVES: To examine the effect of an employer sponsored, community phar-
macy based medication therapy management program (MTM) on clinical outcomes 
in patients with diabetes. METHODS: A one year prospective, pre-post longitudinal 
study. Study Participants were employees and dependents of the City of Toledo in 
Ohio who received care at local independent pharmacies and were seen every three 
months. Enrolled participants had diabetes and/or other comorbid conditions. Data 
collected: clinical (A1c, blood pressure, BMI), social (caffeine and alcohol intake, 
exercise and smoking habits, etc.), process measures (podiatrist, ophthalmologist, 
and dentist visits). Data was analyzed using SPSS v. 16.0. Descriptive statistics and 
Friedman tests were used. Data was analyzed for baseline, 6 months, and 12 months. 
RESULTS: One hundred and one patients enrolled at baseline. Mean A1c improved 
from 7.77 to 7.5 (p = 0.866). Patients with uncontrolled A1c at baseline improved 
from a mean of 8.87 to 8.18 (p = 0.247) at baseline and 12 months. Systolic blood 
pressure improved from 136.17 mmHg to 130.57 mmHg (p = 0.189) and signiﬁ-
cantly improved for patients with baseline SBP ≥ 140 mmHg (p < 0.001). Diastolic 
blood pressure improved from 84.4 mmHg to 80.2 mmHg (p = 0.252) and signiﬁ-
cantly improved for patients with baseline DBP ≥ 90 mmHg (p < 0.001). Social 
measures showed a 34.15% decrease in caffeine intake and 44.12% increase in 
exercise habits. There was a 35.90% increase in podiatrist visits, a 13.51% increase 
in dental visits, and a 29.73% increase in ophthalmologist visits. Use of sick days 
decreased from 1.12 ± 5.32 days per 3 months to 0.09 ± 0.39 (p = 0.368). CON-
CLUSIONS: This community pharmacy MTM program has shown improved out-
comes for patients who participated in pharmacist-guided interventions over a one 
year time period.
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OBJECTIVES: Opioids have commonly been used to treat chronic pain conditions, 
including diabetic peripheral neuropathic pain (DPNP), but tolerance issues have 
limited their use by providers. Newer classes of drugs are now approved for DPNP 
therapy, but no published data currently exists that assess changes in the utilization 
of opioid therapy following treatment with these newer agents. This study compared 
the use of opioids between DPNP patients who initiated treatment with duloxetine 
versus other standard of care (SOC) DPNP treatments. METHODS: This retrospective 
cohort study assessed commercially-insured DPNP patients aged 18 to 64 over a 1-year 
follow-up period who initiated treatment with either duloxetine or other SOC treat-
ments (tricyclic, venlafaxine, gabapentin, pregabalin) between March 1,2005 and 
December 31, 2005. Initiation was deﬁned as a 90-day period without available study 
medication. Dispense date of the ﬁrst study medication initiation was denoted as the 
index date. Selected patients had 12 months continuous enrollment before and after 
the index date, and no opioid pill coverage during the 90 days prior to initiation. 
Patients were matched to duloxetine-treated patients via propensity scoring, control-
ling for demographics, comorbidities, prior health care utilization and costs, and 
medication history. RESULTS: The matched sample included 117 patients in each of 
the duloxetine and SOC cohorts. Compared with SOC patients, duloxetine-treated 
patients were less likely to use any opioids (52.1% vs. 84.6%, p < 0.05) over the 
12-month post-index period. Duloxetine-treated patients, on average, had 2 fewer 
opioid prescriptions dispensed, 27 fewer days on opioids, 120 days greater delay in 
subsequent opioid use, and 1816mg lower morphine equivalent dosage than SOC 
patients (all p < 0.05). Also, duloxetine-treated patients had signiﬁcantly lower total 
($18,623 vs. $30,602, p < 0.05) and outpatient costs ($7,371 vs. $15,343, p < 0.05). 
CONCLUSIONS: Duloxetine treatment is associated with deferred and reduced 
opioid use among DPNP patients. Patients initiated on duloxetine also had lower 
health care costs.
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OBJECTIVES: The objective of this study was to evaluate whether Medicaid coverage 
gap is associated with higher risks for diabetes-speciﬁc hospitalizations and all-cause 
mortality among working-aged adults (i.e., those aged 19–64 years) with diabetes. 
METHODS: Using administrative claims data, we conducted a retrospective cohort 
study of working-aged adults with diabetes and who were enrolled in a state Medicaid 
program. Coverage gap was deﬁned as at least one month interruption in their Med-
icaid enrollment from January 2002 to December 2003. The primary outcomes of 
interest were diabetes-speciﬁc hospitalization and all-cause mortality during follow-up 
(January to December 2004). Multivariate regression analyses were performed to 
assess the independent association between adherence to statin and outcome measures. 
Key confounding variables include age, gender, race, comorbidities (measured using 
Charlson Comorbidity Index), prior hospitalization due to diabetes, and use of medi-
cations essential to diabetes management including oral hypoglycemic agents, insulin, 
antihypertensive agents, and statins. RESULTS: A total 24,996 patients were included 
in the study. Mean age 50.2 ± 10.3 years, 29.7% male, 70.3 female; 30.3% white, 
59.3% black. About 86% had continuous Medicaid coverage and 14% had at least 
one month gap in their Medicaid coverage. During follow-up, those with at least 
one-month in their coverage were 16.2% less likely (OR: 0.838; 95%CI: 0.714–0.985) 
to have diabetes-speciﬁc hospital admissions and 44.9% less likely (OR: 0.551; 
95%CI: 0.430–0.706) to have all-cause mortality during the follow up period. CON-
CLUSIONS: The results from this study suggest that gaps in Medicaid coverage are 
not associated with higher risks for diabetes-speciﬁc hospitalizations and all-cause 
mortality in the follow up period. However, the study lacked information on why 
coverage gaps occurred and whether individuals with coverage gaps transitioned to 
other insurance coverage.
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OBJECTIVES: To examine racial and ethnic disparities in quality of health care 
(receipt of diabetes services, timeliness, and patient centeredness) among adults with 
diabetes in the U.S. in the years of 2005 and 2006. METHODS: The 2005 and 
2006 Medical Expenditure Panel Survey (MEPS) full-year consolidated data ﬁles 
including the Diabetes Care Survey and the Self-Administered Questionnaire were 
combined and analyzed. The racial and ethnic disparities in receipt of recommended 
diabetes services (A1C test, foot exam, eye exam, lipid proﬁle, and inﬂuenza immu-
nization), timeliness, and patient centeredness were examined. Chi-square test and 
logistic regression were conducted to evaluate the disparities before and after control-
ling for the confounding factors (age, gender, family income, education, health insur-
ance coverage, residential location, and language spoken most often at home). 
RESULTS: In 2005–2006, the racial and ethnic disparities in quality of health care 
among U.S. adults with diabetes still exist even after controlling for demographic 
and socioeconomic factors. African Americans and Hispanics were less likely to 
receive recommended diabetes services and patient-centered health care than Whites. 
African Americans had more foot examinations than Whites and Hispanics. There 
was no signiﬁcant difference in timeliness of health care among racial and ethnic 
groups. CONCLUSIONS: Racial and ethnic disparities in receipt of recommended 
diabetes services and patient centeredness of health care among adults with diabetes 
remained in the U.S. in 2005–2006. Age, family income, health insurance coverage, 
education, residential location, and English-speaking were correlated with racial and 
ethnic disparities. As this study is focused on disparities among only Whites, African 
Americans, and Hispanics, future studies comparing possible differences among other 
U.S. ethnic groups (e.g., American Indians or Alaska Natives) are needed using 
more-year, larger databases.
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OBJECTIVES: The objective of this study was to evaluate the main effect of health 
insurance plan type on health resource utilization (emergency room (ER) visit or 
hospital admission) in privately insured patients with Type 2 diabetes between the 
ages of 18 to 64 years. The outcomes of interest were the odds of an emergency room 
visit or a hospital admission associated in patients with Type 2 diabetes. METHODS: 
The data source was the 2000–2001 MarketScan database, which is comprised of 
administrative claims data for over 2.5 million privately insured individuals in the 
United States. The odds of an emergency room visit or hospital admission were evalu-
ated using multiple logistic regression models speciﬁed to control for demographic and 
clinical characteristics of the target patient population. A propensity score analysis 
using the stratiﬁcation approach was also done to further control for selection bias. 
RESULTS: After adjusting for the covariates, patients enrolled in FFS plans were 
